CAR T cell immunotherapy for human cancer

By C. June, Roddy S. O’Connor, O. Kawalekar, Saba Ghassemi, M. Milone. Science, 2018

2,700 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

CAR-T cell therapy: current limitations and potential strategies (2021, background): “One strategy to ameliorate these limitations is through the utilization of delivery routes other than systemic delivery as local administration (1) eliminates the need for CAR-T cells to traffic to disease sites and (2) limits on-target off-tumor toxicities as the CAR-T cells’ on-target activity is ”
Cytokines in clinical cancer immunotherapy (2018, background): “…relegated the clinical use of these cytokines in favour of targeted therapy and immune checkpoint inhibitors.9,10 www.nature.com/bjc Received: 19 June 2018 Revised: 4 October 2018 Accepted: 8 October 2018 Published online: 9 November 2018 1Immunology and Immunotherapy Program, Center for…”
CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment (2019, background): “intracellular costimulatory domains (4-1BB and CD28), the ζ chain, a 2A linker, and the gene of interest to be coexpressed (61, 62).”